Who
Neil Lerner
Chief Accounting Officer
Company insider
Files Form 4 as: Chief Accounting Officer, Compass Therapeutics; VP - Finance, Psychemedics.
In numbers
- Trades disclosed
- 53
- Buys
- 8
- Sells
- 5
- Bought
- $242K
- Sold
- $309K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 17 Mar 2011
- Last trade
- 1 Oct 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 2 Oct 2026 | CMPX Compass TherapeuticsBiotechnology | SEC FORM 4 Bought | $18K20,000 at $0.92 | filing |
| 24 Sep 2026filed 25 Sep 2026 | CMPX Compass TherapeuticsBiotechnology | SEC FORM 4 Bought | $2,8502,500 at $1.14 | filing |
| 24 Sep 2026filed 25 Sep 2026 | CMPX Compass TherapeuticsBiotechnology | SEC FORM 4 Bought | $2,8502,500 at $1.14 | filing |
| 29 Apr 2026filed 30 Apr 2026 | CMPX Compass TherapeuticsBiotechnology | SEC FORM 4 Bought | $28K15,000 at $1.89 | filing |
| 29 Apr 2026filed 30 Apr 2026 | CMPX Compass TherapeuticsBiotechnology | SEC FORM 4 Bought | $28K15,000 at $1.89 | filing |
| 29 Apr 2026filed 29 Apr 2026 | CMPX Compass TherapeuticsBiotechnology | SEC FORM 4 Code A | $28K15,000 at $1.89 | filing |
| 29 Apr 2026filed 29 Apr 2026 | CMPX Compass TherapeuticsBiotechnology | SEC FORM 4 Code A | $28K15,000 at $1.89 | filing |
| 2 Jan 2026filed 5 Jan 2026 | CMPX Compass TherapeuticsBiotechnology | SEC FORM 4 Code A | $323K62,500 at $5.17 | filing |
| 2 Jan 2026filed 5 Jan 2026 | CMPX Compass Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —435,000 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | CMPX Compass Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —435,000 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | CMPX Compass TherapeuticsBiotechnology | SEC FORM 4 Code A | $323K62,500 at $5.17 | filing |
| 7 Apr 2025filed 8 Apr 2025 | CMPX Compass TherapeuticsBiotechnology | SEC FORM 4 Bought | $28K20,000 at $1.42 | filing |
| 11 Feb 2025filed 13 Feb 2025 | CMPX Compass Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 11 Nov 2020filed 13 Nov 2020 | Psychemedicsoption or derivative | SEC FORM 4 Code A | —3,000 at $0.00 | filing |
| 11 Nov 2020filed 13 Nov 2020 | Psychemedics | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 4 May 2020filed 6 May 2020 | Psychemedics | SEC FORM 4 Code F | $2,294399 at $5.75 | filing |
| 3 May 2019filed 7 May 2019 | Psychemedics | SEC FORM 4 Code A | —3,500 at $0.00 | filing |
| 3 May 2019filed 7 May 2019 | Psychemedics | SEC FORM 4 Code F | $1,632154 at $10.60 | filing |
| 30 Apr 2019filed 2 May 2019 | Psychemedics | SEC FORM 4 Code F | $3,492301 at $11.60 | filing |
| 12 Mar 2019filed 13 Mar 2019 | Psychemedics | SEC FORM 4 Sold | $21K1,412 at $15.06 | filing |
News
Compass Therapeutics (NASDAQ:CMPX) CAO Neil Lerner Buys 20,000 Shares of Company Stockdailypolitical.com · 2 Oct 2026Compass Therapeutics, Inc. (NASDAQ:CMPX) Stock Has Average Target Price of $10.21CMPX · dailypolitical.com · 11 Oct 2026
1 headline in the last 90 days name Neil Lerner; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.